A new study reveals that specific molecular signatures in the immune system and noncoding RNA expression patterns can predict which precancerous colorectal lesions will develop into cancer—before malignancy appears. Published in Science Translational Medicine, the research analyzes multiple patient cohorts to establish these predictive biomarkers.
The findings show that immune microenvironment changes precede malignant transformation, providing clinicians with measurable indicators of cancer risk. Noncoding RNA patterns offer additional molecular signatures for early identification. This dual-biomarker approach enables stratification of patients into risk categories, allowing personalized surveillance strategies. For patients with precancerous lesions, these molecular markers could determine intensity of monitoring and preventive interventions, making this research a potential game-changer in colorectal cancer management and prevention.
Read the full article on GMJ Newsroom.
Was this article helpful?
